ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the pricing of its previously announced public offering of 187,500,000 common shares (or common share equivalents) of the Company, together with short-term warrants to purchase up to 187,500,000 common shares, at a combined public offering price of $0.16 per share and accompanying warrant. Readers are cautioned that this list of risk factors should not be construed as exhaustive. All of the shares to be sold in the offering are to be sold by the company. Introducing highly sensitive, species specific assays for the diagnosis of thyroid disease in dogs and cats and adrenal disease in dogs. ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a … The FDA said the subcommittee will consider and discuss issues relating to the development of each product for pediatric use and provide guidance to facilitate the formulation of written requests for pediatric studies, if appropriate.

IPSEN S A/S ADR (OTC: IPSEY) said the FDA granted the Fast Track designation for the investigational use of liposomal irinotecan in combination with 5- fluorouracil/leucovorin and oxaliplatin, for patients with previously untreated, unresectable, locally advanced and metastatic pancreatic ductal adenocarcinoma. In February 2020, the Company announced the completion of a $2.5 million offering of common shares and warrants. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. © 2020 GlobeNewswire, Inc. All Rights Reserved. 119. The company added it has launched the testing solution and that its testing service will be made available through Picture Genetics, its consumer-initiated genetic testing platform, beginning next week. The company said the investigational asset has the potential to address the two critical elements of COVID-19 - high viral replication and uncontrolled inflammatory response that ensues after infection.
GAAP”). The decrease was primarily due to a reduction in share-based compensation which was $155,022 for the three months ended March 31, 2020 compared to $2,341,104 for the comparable period in 2019. Due to our focus on our TRUFORMATM platform, we have reduced administrative headcount and associated activities and therefore, we expect that general and administrative expense will decrease in the remainder of 2020. This panel is intended to assay the function of the pancreas, proximal small intestine, and distal small intestine.

Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. There is no public trading market for the warrants, and Zomedica does not expect a market to develop. The agreement to pursue development of the new assays has triggered the final $2 million milestone payment under Zomedica’s Development and Supply Agreement with Qorvo. The decrease was primarily due to expenses incurred in the three-month period ended March 31, 2019 relating to filings with the Securities and Exchange Commission which did not recur in the comparable 2020 period. The increase resulted primarily from the repurchase of our previous prepaid lease for $1,002,113 and cash received on the sale of property and equipment for $5,400.

Except for statements of historical fact, this news release contains certain "forward-looking information" or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Here's a roundup of top developments in the biotech space over the last 24 hour.
Anne de Vos, DVM: It’s all about perspective, Zomedica Announces Shareholder Meeting Voting Results, Winners of Zomedica-Sponsored Veterinary Innovation Awards Announced by NAVC and The Veterinary Innovation Council, Helping Veterinary Practices Thrive: An Interview with Beverly Hollis, DVM. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to provide veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. Except for statements of historical fact, this news release contains certain "forward-looking information" or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law.

Sinovac Makes Headway In Coronavirus Vaccine Race With Positive Preliminary Phase 1/2 Results, The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs, The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout, The Daily Biotech Pulse: Patent Award For Theratechnologies, Enzo Biochem's Q4, Codiak Debuts, 9 Biotech Stocks With Material Catalysts In Q4, The Daily Biotech Pulse: J&J Pauses Coronavirus Vaccine Studies, Voyager's Huntington's Disease Study Placed On Hold, Altimmune Vaccine Data, The Week Ahead In Biotech: J&J Earnings Kickstarts Pharma Earnings, More IPOs In The Pipeline, Cannabis Proves To Popular Among Newlyweds — And Their Pets, Privacy Policy / Do Not Sell My Personal Data. For complete financial results, please see Zomedica’s filings on EDGAR and SEDAR or visit the Zomedica website at www.ZOMEDICA.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive. Readers are cautioned not to place undue reliance on forward-looking information. Net cash from financing activities for the three months ended March 31, 2020 was $2,151,780, compared to $3,006,828 for the three months ended March 31, 2019, a decrease of $855,048 or 28%. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. By creating an account, you agree to theTerms of Service and acknowledge our Privacy Policy.